Nark Pharmaceuticals Private Limited, a active private limited company, was established on 08 December 2010 in Ernakulam, Kerala, India. Engaging in wholesale within the trade sector, it holds CIN: U51397KL2010PTC027169. Registered under ROC Roc Ernakulam. it is unlisted. It has an authorized capital of ₹7.50 M and a paid-up capital of ₹5.30 M.
It upholds a compliant status. Employing 2 professional, Its leadership includes Ritika Anil Kumar (Director), Navakumar Narayanan (Managing Director), Sudhakara Reddy Dodla (Director). Past directors included Ritika Anil Kumar, Dinesh Rajendran Nair, Rajesh Kochupurayil Madanan Pillai. It holds ₹1.00 M open charges and no settled loans. Its latest AGM occurred on 23 September 2024, with the balance sheet filed on 31 March 2024. It is based at 28/1270, Kezhupilly Cross Road Kadavanthra, Ernakulam, Kerala, 682020.
U51397KL2010PTC027169
027169
08 December 2010
₹7.50 M
₹5.30 M
Roc Ernakulam
Unlisted
Active
Explore comprehensive insights into Nark Pharmaceuticals Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ritika Anil Kumar | Director | 27 Sep 2018 | Current |
| Navakumar Narayanan | Managing Director | 08 Dec 2010 | Current |
| Sudhakara Reddy Dodla | Director | 20 Jul 2018 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 30 Sep 2019 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2016 | Past |
| Pramod Abcsdd | Director | 10 Feb 2017 | Past |
| Pramod Abcsdd | Additional Director | 26 Sep 2018 | Past |
| Pramod Abcsdd | Additional Director | 26 Sep 2018 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Nark Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 24.12% increase. The company also saw a substantial fall in profitability, with a 55.58% decrease in profit. The company's net worth Soared by an impressive increase of 16.58%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2021, Nark Pharmaceuticals had a promoter holding of 92.45% and a public holding of 7.55%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹1,000,000.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Dec 2018 | State Bank Of India | ₹1.00 M | Open |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Nark Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Nark Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nark Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Nark Pharmaceuticals Private Limited last Annual general meeting of members was held on 23 Sep 2024 as per latest MCA records. was recorded as a recent event.
The activity Nark Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Ernakulam. was completed.
A charge with State Bank Of India amounted to Rs. 1.00 M with Charge ID 100232579 was registered on 29 Dec 2018. was recorded as a recent event.
Ritika Anil Kumar was appointed as a Director was appointed as a Director on 27 Sep 2018 & has been associated with this company since 7 years 2 months . was recorded as a recent event.
Sudhakara Reddy Dodla was appointed as a Director was appointed as a Director on 20 Jul 2018 & has been associated with this company since 7 years 4 months . was recorded as a recent event.
The activity Navakumar Narayanan was appointed as a Managing Director was appointed as a Managing Director on 08 Dec 2010 & has been associated with this company since 14 years 11 months . was completed.
The CIN of Nark Pharmaceuticals Private Limited is U51397KL2010PTC027169.
Nark Pharmaceuticals Private Limited is headquartered at 28/1270, Kezhupilly Cross Road Kadavanthra, Ernakulam, Kerala, 682020.
Nark Pharmaceuticals Private Limited was incorporated on 08 December 2010.
The current directors of Nark Pharmaceuticals Private Limited are
The primary industry of Nark Pharmaceuticals Private Limited is Trade.
Nark Pharmaceuticals Private Limited is unlisted.
The authorized capital of Nark Pharmaceuticals Private Limited is ₹7.50 M, and the paid-up capital is ₹5.30 M.
The compliance status of Nark Pharmaceuticals Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX